PremiumCompany AnnouncementsNovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes NovaBay reports Q3 EPS (60c), two estimates (30c) NovaBay accepts revised transaction proposal from PRN PremiumCompany AnnouncementsNovaBay Pharma Plans Special Meeting for Asset Sale Biotech Alert: Searches spiking for these stocks today Morning Movers: Apellis slips following negative CHMP opinion PremiumThe FlyNovaBay reports Q2 EPS ($1.37), two estimates ($1.22) NBY Earnings Report this Week: Is It a Buy, Ahead of Earnings? NovaBay reports record Amazon Prime Day sales